Literature DB >> 7094500

Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone.

A Tamsen, U Bondesson, B Dahlström, P Hartvig.   

Abstract

The effects of anaesthesia and surgery on the pharmacokinetics of ketobemidone were studied in 12 patients. Plasma ketobemidone concentrations were assayed with a mass-fragmentographic method. The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h. In the postoperative period Vd(area) decreased to 3.7 +/- 0.4L/kg and the terminal half-life to 2.1 +/- 0.4 h. Plasma clearance (Clp) did not change significantly, peroperative Clp being 18 +/- 4.3 ml/min/kg and postoperative Clp being 22 +/- 7.5 ml/min/kg. The pharmacokinetics of ketobemidone were not influenced by the addition of a spasmolytic agent in the commercial combination ketobemidone preparation 'Ketogin'. Postoperative pain was relieved in 15 patients by patient-controlled intravenous administration of ketobemidone by means of a programmable drug injector. The mean ketobemidone consumption was 2.3 +/- 0.8 mg/h, which produced a mean plasma concentration of 28 +/- 11 mg/ml. Pseudosteady-state plasma concentrations of ketobemidone were established with a mean minimum effective concentration (MEC) of 25 +/- 11 ng/ml. Ketobemidone 'plain' and 'Ketogin' did not differ significantly in these respects. Analgesia was considered by all patients to be satisfactory.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094500     DOI: 10.2165/00003088-198207030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  19 in total

1.  The effect of hypercapnia on estimated hepatic blood flow, circulating splanchnic blood volume, and hepatic sulfobromophthalein clearance during general anesthesia in man.

Authors:  R M EPSTEIN; H O WHEELER; M J FRUMIN; D V HABIF; E M PAPPER; S E BRADLEY
Journal:  J Clin Invest       Date:  1961-03       Impact factor: 14.808

2.  The analgesic properties and addiction liability of ketobemidone and morphine.

Authors:  P PELTOLA; P SOISALO
Journal:  AMA Arch Intern Med       Date:  1958-04

3.  Alterations in distribution volume and biological half-life of cortisol during major surgery.

Authors:  H Kehlet; C Binder
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

4.  Effects of heat and exercise on the elimination of pralidoxime in man.

Authors:  R D Swartz; F R Sidell
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

5.  Mass fragmentographic method for the determination of ketobemidone in plasma.

Authors:  U Bondesson; P Hartvig
Journal:  J Chromatogr       Date:  1979-11-07

6.  Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

7.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

8.  Influence of abdominal surgical trauma and intra-operative infusion of glucose on splanchnic glucose metabolism in man.

Authors:  H Stjernström; L Jorfeldt; L Wiklund
Journal:  Clin Physiol       Date:  1981-10

9.  Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.

Authors:  P Anderson; S Arnér; U Bondesson; L O Boréus; P Hartvig
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

10.  Clinical pharmacokinetics and oral bioavailability of ketobemidone.

Authors:  U Bondesson; S Arnér; P Anderson; L O Boréus; P Hartvig
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

View more
  9 in total

1.  The pharmacokinetics of ketobemidone in critically ill patients.

Authors:  Ayman Al-Shurbaji; Leif Tokics
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

Review 2.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  Combined spinal epidural block versus spinal and epidural block for orthopaedic surgery.

Authors:  B Holmström; K Laugaland; N Rawal; S Hallberg
Journal:  Can J Anaesth       Date:  1993-07       Impact factor: 5.063

4.  Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays.

Authors:  Marthe M Vandeputte; Mattias Persson; Donna Walther; Svante Vikingsson; Robert Kronstrand; Michael H Baumann; Henrik Gréen; Christophe P Stove
Journal:  Arch Toxicol       Date:  2022-01-24       Impact factor: 5.153

5.  Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

6.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

7.  Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine.

Authors:  B Dahlström; A Tamsen; L Paalzow; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

Review 8.  Newer methods of delivery of opiates for relief of pain.

Authors:  P J Slattery; R A Boas
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

Review 9.  Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors.

Authors:  Cynthia Wei-Sheng Lee; Ing-Kang Ho
Journal:  Mol Pain       Date:  2013-09-08       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.